Applikon Biotechnology

Belkins
Applikon Biotechnology is a privately owned Dutch company developing, manufacturing and supplying bioreactor systems for both research and production use. With the stability that Applikon has shown you can rest assured of dependable service and support in the future. Starting in 1973 Applikon has grown from a small sized company supplying laboratory instrumentation to a dynamic worldwide enterprise capable of supplying a broad and diverse line of bioreactor systems.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

news image

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

news image

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

news image

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

news image

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More
news image

CELL AND GENE THERAPY

PACBIO ACQUIRES OMNIOME, A DNA SEQUENCING STARTUP, FOR UP TO $800 MILLION

PacBio | July 26, 2021

Pacific Biosciences has had no trouble growing its business on its own in the year and a half since its acquisition by Illumina was blocked by the Federal Trade Commission due to concerns that the combination would establish a monopoly in DNA sequencing. Earlier this year, the sequencer manufacturer received a staggering $900 million investment from SoftBank—a commitment almost as large as the $1.2 billion promised by Illumina for the planned acquisition. PacB...

Read More
news image

BIOLOGICAL DYNAMICS EXPANDS BIOMARKERS RESEARCH TO DEVELOP ASSAYS FOR DETECTION AND QUANTIFICATION OF BLOOD-BASED BIOMARKERS

Biological Dynamics | July 30, 2020

Biological Dynamics, Inc., an innovative diagnostic company committed to improving global health, announces a new biomarkers program designed for drug development applications in Alzheimer's Disease (AD). The company will use its proprietary Verita™ platform to develop a portfolio of assays for detection and quantification of blood-based biomarkers associated with AD and other neurodegenerative conditions. The program is funded by the Alzheimer's Drug Discovery Foundation's (AD...

Read More
news image

SPRUCE BIOSCIENCES CLOSES ON $88 MILLION SERIES B ROUND, ADVANCING CAH PROGRAM

BioSpace | February 20, 2020

Spruce Biosciences, based in San Francisco, closed on a Series B financing round worth $88 million. The round was co-led by Omega Funds and Abingworth and supported by existing investors Novo Holdings and RiverVest Venture Partners. New investors included HealthCap Partners, Rock Springs Capital, Surveyor Capital (a Citadel company), Aisling Capital and Sands Capital. In September 2019, the company announced positive results from a Phase IIa, multicenter, 12-week clinical trial of tildacerfont f...

Read More
news image

PRECISION VIROLOGICS AND BHARAT BIOTECH JOINTLY OBTAIN RIGHTS TO INTRANASAL COVID-19 VACCINE TECHNOLOGY

Precision Virologics | September 23, 2020

Biotech startup Precision Virologics, which develops adenovirus-based vaccines in St. Louis, and Bharat Biotech, a vaccine manufacturing giant, jointly obtained rights from Washington University School of Medicine in St. Louis for a novel chimp-adenovirus vaccine for COVID-19. Precision Virologics has optioned rights for USA, Europe, and Japan. Bharat has obtained a license for all other markets. The licensing agreements will lead to rapid clinical development, following the intranasal vaccine c...

Read More